Oruka Therapeutics Inc. (ORKA)
10.07
-0.43 (-4.10%)
At close: Apr 25, 2025, 3:59 PM
10.09
0.20%
After-hours: Apr 25, 2025, 04:05 PM EDT
-4.10% (1D)
| Bid | 7.22 |
| Market Cap | 377.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.6 |
| Volume | 136,402 |
| Avg. Volume (20D) | 289,848 |
| Open | 10.40 |
| Previous Close | 10.50 |
| Day's Range | 9.72 - 10.40 |
| 52-Week Range | 5.49 - 53.88 |
| Beta | 0.42 |
About ORKA
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA....
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 28
Stock Exchange NASDAQ
Ticker Symbol ORKA
Website http://www.orukatx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ORKA stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 336.94% from the latest price.
Stock Forecasts5 months ago
-6.43%
Oruka Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
7 months ago
+9.76%
Oruka Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a $40 price target.